Jump to content

Corcept Therapeutics

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Whisoseryus (talk | contribs) at 11:54, 20 February 2014. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Corcept Therapeutics Inc. is a pharmaceutical company developing products that regulate the effects of cortisol (the stress hormone) and deal with severe metabolic disorders.[1] The company is a publicly traded company on NASDAQ under the symbol "CORT".

Corcept Therapeutics Inc.
Company typePublic
NASDAQ:CORT
IndustryPharmaceutical Industry
Founded1998[2]
HeadquartersUnited States
ProductsPharmaceutics
Websitewww.corcept.com

Treatments

Corcept Therapeutics Inc. has developed treatments mainly focusing on solving metabolic disorders and related problems, and have several experimental and on-sale drugs released.[3]

Main products

One of the principle drugs that the company developed is Korlym, which is an oral daily medication for patients with type II diabetes mellitus or glutose intolerance, and those who failed or might not be appropriate to be under surgery. In 2013, after been applied in the US, the drug was further commercialized to the market outside the States and reached the global medical field, since the company's partnership with Idis Access Program was approved and launched.[4]

Studies on Psychotic Depression

From 1998, the company has been studying the psychotic features of depression and developing oral medication for the symptoms. Recent years, two of the main trials on this were conducted with the drug CORLUX, which is a once-daily treatment given to patients, mainly in the United States.[5]

On other metabolic disorders

The company has also been studying treatment for other metabolic disorders. In April 2005, results of two preclinical studies were announced by the company, demonstrating an effect that can prevent weight gain associated with treatment in olanzapine.[6]

In December 2013, the company announced plans to extend its development program for glucocorticoid receptor (GR) antagonists, including mifepristone, into oncology.[7]

Corporate affairs

Patent rights

In December 2013, Corcept Therapeutics Inc. licensed patent rights with the University of Chicago's Center for Technology Development & Ventures, and started investigating new drug application with the US Food and Drug Administration (FDA), on metastatic TNBC.[8]

References

  1. ^ http://www.corcept.com/
  2. ^ http://finance.yahoo.com/q/pr?s=CORT+Profile
  3. ^ http://www.google.com/finance?cid=660571
  4. ^ http://www.reuters.com/finance/stocks/CORT.O/key-developments/article/2800010
  5. ^ http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=CORT.O
  6. ^ http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=CORT.O
  7. ^ "Corcept Therapeutics Announces Oncology Development Program".
  8. ^ http://www.prnewswire.com/news-releases/CORTmed-announces-acquisition-of-zipsor-diclofenac-potassium-from-xanodyne-pharmaceuticals-Inc.-159919525.html

Category:Publicly traded companies of the United States

Retrieved from "https://en.wikipedia.org/w/index.php?title=Corcept_Therapeutics&oldid=596324684"